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Objective: In peripheral arterial disease (PAD) patients, a limiting factor in the success of percutaneous transluminal
angioplasty (PTA) is the development of restenosis secondary to vascular smooth muscle cell (SMC) proliferation.
Following endothelial damage and platelet activation, there is release of factors and adhesion molecules which affect SMC
proliferation. The aim of this study was to determine the effect of combination antiplatelet therapy (clopidogrel and
aspirin compared with aspirin and placebo) on the ability of plasma from PAD patients undergoing PTA to stimulate
SMCs in vitro. We further aimed to investigate the effect of combination treatment on the levels of circulating adhesion
molecules and factors, which are known to mediate SMC proliferation in experimental models.
Methods: Fifty patients were randomized to receive blinded clopidogrel or placebo, for thirty days, in addition to their
daily 75 mg aspirin. To measure proliferative capacity, diluted plasma was incubated for 15 minutes with 24
hour-growth-arrested rat vascular smooth muscle cells, and extracellular regulated kinase (ERK)1/2 activation was
analyzed by Western blotting at baseline, one hour pre-PTA, one hour, 24 hours and 30 days post-PTA. Plasma
platelet-derived growth factor (PDGF), sE-selectin, intracellular adhesion molecule-1 (sICAM-1), and von Willebrand
factor (vWF) were measured by ELISA, at the same five timepoints. Platelet activation was measured by flow cytometry
of ADP-stimulated platelet fibrinogen binding at baseline and one hour post-PTA.
Results:ADP-stimulated platelet fibrinogen binding was significantly inhibited by clopidogrel before and after PTA. ERK
1/2 activation was significantly increased post-PTA in both the aspirin/clopidogrel and aspirin/placebo groups (P <
.001). There was a statistically significant decrease in PDGF (P  .004), and increase in vWF (P  .026), following
loading with clopidogrel. sICAM-1 levels significantly decreased (P .016) in the aspirin/placebo group following PTA.
There were no other significant changes and also there was no statistically significant difference between the two
treatment groups for each of ERK 1/2, sICAM-1, sE-selectin, or vWF.
Conclusions: This is the first study to show in-vitro ERK 1/2 activation (a surrogate marker of SMC proliferation)
increases post-PTA. Combination antiplatelet therapy had no significant effect on this, although it did reduce PDGF.
Further work is required to evaluate potential therapeutic treatments, which may reduce peripheral PTA-induced smooth
muscle cell activation. (J Vasc Surg 2009;50:861-9.)
Clinical Relevance: High rates of restenosis remain the major limitation of peripheral arterial angioplasty and stenting.
The restenotic lesion occurs secondary to platelet activation, released circulating factors, and subsequent smooth muscle
cell proliferation and migration into the intima. Methods to limit the restenotic lesion are poorly understood. This paper
investigates the effect of PTA on smooth muscle cell activation and the release of factors in plasma which mediate SMC
proliferation. It also examines the effect of combination antiplatelet therapy as a potential therapeutic strategy.In patients with peripheral arterial disease, percutane-
ous transluminal angioplasty (PTA) is a recommended and
commonly used treatment option.1 Despite initially good
clinical and technical results, medium and long term out-
come is limited by the development of restenosis.2 After
PTA, smooth muscle cells (SMCs) in the arterial media
migrate into the intimal layer, where they form a neointima
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doi:10.1016/j.jvs.2009.06.017and the basis of a restenotic lesion.3-5 In order for medial
smooth muscle cells to proliferate and migrate into the
intima they are required to alter their phenotype from
contractile to proliferative.6 Extracellular regulated kinase
(ERK)1/2 is the final step of the mitogen-activated protein
kinase (MAPK) cascade, which is essential for signaling the
stimulus to cellular proliferation.7,8 Animal studies have
demonstrated an increase in SMC activity for variable peri-
ods post-PTA.9-13 To date there have been no studies
measuring SMC stimulation following peripheral PTA in
humans.
Following PTA, endothelial disruption leads to platelet
activation and the subsequent release of platelet derived
growth factor (PDGF), which is a SMC mitogen.2 PDGF
release has also been shown to correlate with vascular SMC
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lebrand factor (vWF) mediates platelet adhesion to the
damaged endothelium and a post-PTA rise in vWF has
been linked with a higher incidence of restenosis.15,16
Monocytes and neutrophils also bind to the damaged en-
dothelium via cellular adhesion molecules, such as intra-
cellular adhesion molecule-1 (ICAM-1)17 and serum E-
selectin. The latter is only expressed on activated endothelial
cells, and has a soluble form that is thought to be both a
marker for endothelial damage, and a precursor of SMC
proliferation.17-23
In patients undergoing coronary angioplasty, dual an-
tiplatelet therapy has been shown to improve the clinical
outcome and reduce the risk of thrombosis (STent Anti-
thrombotic Regimen Study).24 This benefit is seen up to six
months post-procedure and thus may be a result of reduced
neointimal hyperplasia. Current recommendations for the
management of patients with PAD state that all should be
prescribed daily antiplatelet therapy.1,25,26 In the United
Kingdom, the first line treatment is aspirin rather than
clopidogrel mainly due to cost considerations. If improved
patency and decreased neointimal hyperplasia occurs with
dual therapy in patients undergoing coronary PTA, it seems
justifiable to argue that a similar advantage will be gained in
patients undergoing peripheral PTA.We hypothesized that
combination antiplatelet therapy with clopidogrel may
have an inhibitory role on the SMC proliferation that
occurs following PTA induced endothelial damage and
denudation. The aim of this randomized controlled trial
was to determine the effect of combination antiplatelet
therapy (clopidogrel and aspirin) compared with aspirin
alone on the ability of plasma from PAD patients undergo-
ing PTA to stimulate SMCs in vitro. We also wished to
determine the effect on the levels of circulating adhesion
molecules and growth factors that are known to mediate
SMC proliferation in experimental models.
METHODS
One hundred and fifty-three patients were screened for
possible entry into this prospective, randomized placebo-
controlled trial (Fig 1). All patients (with intermittent
claudication), who were due to undergo angioplasty (
stenting) of iliac or femoropopliteal disease segments were
considered for inclusion. Patients were required to be tak-
ing 75mg of aspirin daily and those on warfarin, heparin, or
steroid therapy were excluded. Further exclusion criteria
included: a hemogloblin of less than 10 g/dL; platelet
count less than 150  109/L; an increase in liver function
tests greater than three times the upper limit normal; a
creatinine greater than two times the upper limit normal.
Patients with malignancy, known drug or alcohol abuse,
coagulopathy or bleeding diathesis, an acute illness, or
blood transfusion within 14 days were also excluded as were
those with a history of peptic ulcer disease or other contra-
indication to clopidogrel or aspirin.
Fifty-eight patients with stable intermittent claudica-
tion who were due to undergo angioplasty were recruited
from the Vascular Unit in Aberdeen Royal Infirmary be-tween August 2005 and September 2006. Informed con-
sent was obtained from each patient and at the time of
angiography, fifty of these patients underwent angioplasty,
which was performed by one of two experienced Consul-
tant interventional radiologists. ABPIs were performed pre-
PTA and less than 24 hours post-PTA by fully trained
vascular technicians. The procedure was deemed to be
successful if a patient’s ABPI increased by at least 0.1.
Ethical approval was obtained from the North East of
Scotland Ethical Committee and theMedicine andHealth-
care Products Regulations Agency provided clinical trial
authorization. In addition to their daily 75 mg aspirin,
patients were randomized externally by the trial drug sup-
pliers to receive either 1) clopidogrel (300 mg loading
dose) at least 12 hours before angioplasty, followed by 75
mg aspirin daily) or 2) placebo, in both cases for a 30 day
period. The radiologists, research fellow, vascular, and lab-
oratory technicians were all blinded to which drug (placebo
or clopidogrel) the patients were allocated to. Compliance
was assessed by counting the number of remaining tablets
which were returned at the 30 day review appointment. All
patients were on statin therapy, which had been com-
menced greater than four weeks prior to randomization.
STUDY DESIGN
Venous blood samples were taken at the following time
points: at baseline (when patients were taking aspirin only),
one hour pre-PTA (at least 12 hours following trial drug
loading), and post-PTA at one hour, 24 hours, and 30 days.
All the assays described below (apart from platelet fibrino-
gen binding) were measured at each time point. Within 15
minutes of venepuncture, the samples were centrifuged
twice at 2500G for 15 minutes at 10oC. This double-spun
plasma was then aliquoted and snap frozen at 70oC.
Whole blood for flow cytometry measurement was ana-
lyzed immediately. Following study completion, samples
from all timepoints for each patient were thawed and
analyzed together (being repeated in duplicate or triplicate
Fig 1. Consort flowchart of patient throughput.in separate assays). The following assays were performed:
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Cell culture. Diluted plasma (5% in serum free media)
was incubated for 15 minutes with (24 hour-growth-
arrested, fully confluent, passage 3-15) rat vascular SMCs
(A7r5 line). Protein was then extracted using previously
described techniques27 to allow Western blot analysis of
ERK 1/2 (MAP Kinase) activation. This activation level
was quantified by referencing as a percentage of the nega-
tive control, on optical density reading of a colorimetric
(MTT) assay (See Fig 2). Each assay had a constant nega-
tive control (serum free medium) and positive control (10%
fetal calf serum) as well as a reference control (5% pooled
plasma). The mean level of activation was used for analysis.
The intra-assay co-efficient of variation (CV) was5%, and
the inter-assay CV was 5%.
Markers of endothelial function
Plasma PDGF, sE-selectin, sICAM-1 and vWF were
measured by ELISA. vWF28 was measured by an in-house
enzyme-linked immunosorbent assay (ELISA) using rabbit
anti-human polyclonal antibodies from Dako (Glostrup,
Denmark). Module sets and standards for sE-selectin
(BMS205MST), and sICAM-1 (BMS201MST) were ob-
tained from Bender Medsystems (Vienna, Austria) and
development kit for Human PDGF-BB Duoset DY220
from R&D Systems, Inc. (Minneapolis, Minn, USA). Nor-
mal pooled plasma from at least 20 donors was used as
quality control on each assay plate. Each individual pa-
tient’s samples were analyzed together at a single timepoint
to minimise between-run bias. All samples and standards
were assayed in duplicate and mean absorption was calcu-
lated. The lower limit of detection of the assays was 15
pg/ml for PDGF, 0.8 ng/ml for sE-selectin, and 6.25
ng/ml for sICAM-1. The inter-assay CV in our own labo-
ratory was 9.0% for vWF, 8% for PDGF, 6.2% for sE-
selectin, and 4.1% for sICAM.
Markers of platelet activation
Whole blood flow cytometry was performed using the
Coulter Epics XL-MCL Flow Cytometer (Beckman
Coulter Inc, Brea, Calif, USA). The percentage of platelets
binding fibrinogen in unstimulated diluted whole blood
and following ex-vivo stimulation with ADP (1  105
mol/L) was measured, as previously described.29,30 The
inter-assay CV was 5.7%. Aspirin does not affect ADP-
stimulated fibrinogen binding. Clopidogrel is a non-
Fig 2. Example assay of ERK 1/2 activation. Upper band 
ERK2; Lower band  ERK1; Darker/wider band  greater level
of activation/phosphorylation.competitive platelet ADP-receptor inhibitor, and as such areduction in ADP-stimulated fibrinogen would be ex-
pected if patients were compliant and responsive to clopi-
dogrel therapy.
Statistical analysis
Power calculation. No published studies involving
ERK 1/2 were originally available to assist in the power
calculation. However, based on the 49% to 57% reduction
in ADP-stimulated fibrinogen binding in patients on com-
bination antiplatelet therapy, previously described by
Moshfegh et al in 2000,31 it was calculated that 50 subjects
would be required (25 per group) to assess the difference
between, aspirin/clopidogrel, and aspirin/placebo ( 80%,
at a 5% level of significance).
Statistical analysis was performed using SPSS (SPSS
Inc., Chicago, Ill, USA) version 16.0, under the supervi-
sion of a statistician within the department of Public
Health, University of Aberdeen. Parametric data are pre-
sented as mean and standard deviation (for describing
central tendency and spread) and similarly non-parametric
data are presented as medians and inter-quartile ranges.
Statistical significance is described at the 5% probability
level. Statistical analysis of baseline demographic and clini-
cal parametric data was performed using Students’ t test
and X2 testing for comparison of proportions. Non-
parametric data were analysed using Friedman’s test and be-
tween time-point comparisons were performed using the
Wilcoxon signed-rank test. The Mann-Whitney U test was
used to assess differences between the placebo and clopi-
dogrel group. Multivariate analysis was performed to en-
sure that results were not influenced by any differences
between treatment groups. Consequently, all patient de-
mographics (listed in Table I) and measures of disease
severity (Tables I and II) as well as procedural success were
analyzed to determine effects of all variables on the mea-
sured responses of interest. Missing data were excluded
from analysis.
RESULTS
Of the 58 patients recruited into the study, eight pati-
ents did not undergo angioplasty due to progression of
their lesion or marked infragenicular disease (Fig 1). Five of
these had been randomized to aspirin/clopidogrel and
three patients to the aspirin/placebo group. The patient
demographics are shown in Table I. It was noted that there
was a significantly higher proportion of patients with dia-
betes in the group randomized to aspirin/clopidogrel (P
.044). Details of the type of lesions treated and severity of
the underlying disease are shown in Table II.
Protocol deviations
All 50 patients had venous blood sampling performed
at baseline, one hour pre-PTA, and one hour post-PTA.
Only 56% (28/50) of patients (14 in each treatment arm)
were available for venous blood sampling at 24 hours
post-procedure, and 62% (31/50, 15 aspirin/clopidogrel,
16 aspirin/placebo) at 30 days post-procedure. Reasons
given for non-attendance were predominantly an unwill-
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ability following discharge on the day of the procedure.
Thus in the paper, baseline, one hour pre-PTA, and one
hour post-PTA results are compared for all (n  50)
patients. A longitudinal subgroup analysis for those pa-
tients who have complete samples at all five timepoints (n
28, 14 in each group) is also presented.
Ankle-brachial pressure index (ABPI) results were
available for 44/50 patients following angioplasty. Based
on post-procedure ABPIs, 14 patients in the aspirin/clopi-
dogrel group had a successful PTA and seven did not. In
the aspirin/placebo group, 12 patients had a successful
PTA and 11 did not. This did not represent a statistically
significant difference (x-test P  .329). Of those 18 pa-
tients who did not have a rise in ABPI of greater than 0.1,
all but one were considered to be technically successful
procedures on completion angiography, and that patient
did not require further intervention. Of the remaining
patients (who underwent angioplasty [ stenting] of a
Table I. Baseline clinical characteristics in combined grou
Characteristic Total (n  50) Asp
Male:female 2.6:1 (36:14)
Mean age/years (range) 66.4 (41-86) 6
Smoking status
Non-smoker 3 (6)
Ex-smoker 28 (56)
(%) Current 19 (38)
Diabetes (%) 16 (32)
Mean cholesterol (SD) 4.80 (1.43)
Mean BMI (SD) 28.0 (5.05)
Median ipsilateral ABPI (IQR) 0.60 (0.52-0.69)
ABPI, Ankle-brachial pressure index; BMI, body mass index; IQR, interqua
*X-squared test.
#Student’s independent t-test for comparison of means.
Mann Whitney test for between group comparisons.
Table II. Disease and treatment classification
Total (n  50)
Median ipsilateral ABPI pre-PTA (IQR) 0.60 (0.52-0.69)
Median ipsilateral ABPI post-PTA (IQR) 0.79 (0.61-0.9)
TASC classification1
TASC A 17
TASC B 14
TASC C 9
TASC D 4
Unclassifiable 6
Intervention
PTA only 27
Stenting 23
Site of disease treated
Aortoiliac segment 22
Femoropopliteal segment 26
Both 2
ABPI, Ankle-brachial pressure index; IQR, interquartile range; PTA, percu
*Mann Whitney test for between group comparisons.
#X-squared test.proximal iliac [n  8], or superficial femoral [n  5]lesion), there was marked infragenicular disease in 13 pa-
tients and all had clinical benefit. The four remaining
patients had a subintimal PTA or stenting which occluded
within 30 days. Two of these patients required bypass
surgery and two were treated conservatively.
Testing clopidogrel responsiveness: ADP-stimulated
platelet fibrinogen binding
Baseline and one hour post-PTA samples were used to
measure ADP-stimulated platelet fibrinogen binding. An-
gioplasty has previously been shown to have no effect on
ADP stimulated fibrinogen.32 Likewise, in this study, ADP-
stimulated fibrinogen binding was unchanged following
angioplasty in the aspirin/placebo group. Median (inter-
quartile range) values at baseline were: 48.75 (33.2-58.95)
and 46.1 (29.55-58.1) at one hour post-PTA (P  .304,
Wilcoxon signed ranks test). However, there was a signifi-
cant reduction in patients randomized to aspirin/clopi-
dogrel (compared with aspirin/placebo). In this group, the
treatment arms
lacebo (n  26) Aspirin/clopidogrel (n  24) P value
(16:10) 5:1 (20:4) .086*
(53-83) 64.79 (41-86) .284#
(8) 1 (4)
(46) 16 (67) .342*
(46) 7 (29)
(19) 11 (46) .044*
(1.01) 4.95 (1.77) .465#
(4.26) 29.21 (5.65) .117#
(0.52-0.68) 0.56 (0.52-0.72) .880
ange; SD, standard deviation.
rin/placebo (n  26) Aspirin/clopidogrel (n  24) P value
0.60 (0.52-0.68) 0.56 (0.52-0.72) .880*
0.69 (0.56-0.84) 0.85 (0.65-0.96) .072*
10 7 .653#
7 7
3 6
3 1
3 3
13 14 .555#
13 10
13 9 .670#
12 14
1 1
s transluminal angioplasty; TASC, TransAtlantic Inter-Society Consensus.p and
irin/p
1.6:1
7.88
2
12
12
5
4.65
27.0
0.60
rtile rAspi
taneoumedian (interquartile range) values at baseline compared to
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(15.73-44.15) respectively (P  .001).
Markers of smooth muscle cell stimulating capacity of
plasma
In the aspirin/clopidogrel group at baseline, two of the
patients were found to have maximal ERK 1/2 activation
(ie, equal expression to positive control: 10% fetal calf
serum). These patients have been consequently excluded
from the analysis. A 300 mg dose of clopidogrel had no
effect on ERK activation; thus in both groups there was no
difference in ERK 1/2 activation between baseline and
pre-PTA timepoints. Following angioplasty, ERK 1/2 ac-
tivation significantly increased at the one hour post-PTA
timepoint compared with baseline and pre-PTA in both the
clopidogrel and placebo group (Table III).
There was no significant difference in ERK activa-
tion between the aspirin/clopidogrel and aspirin/placebo
groups at baseline, pre-PTA, or one hour following PTA.
Multivariate analysis was performed for age, gender,
weight, BMI, ipsilateral ABPI, diabetes, smoking status,
and procedure (PTA or stent). This revealed that any
demographic differences between the two treatment
groups (in particular, in terms of differing incidence of
diabetes) did not account for any variability in observed
ERK 1/2 levels. A subgroup analysis of the (n  28)
patients who were sampled at all five timepoints revealed a
similarly significant increase in ERK levels post-PTA, which
persisted in both groups at 24 hours and 30 days post-
angioplasty.
PDGF
In 10/24 in the aspirin/clopidogrel group, and 9/26
in the aspirin/placebo group, the level of PDGF was at or
Table III. Smooth muscle cell stimulation as measured by
Treatment arm Baseline Po
Aspirin/Clopidogrel N  22 150 (115-300)
Aspirin/Placebo N  26 187 (145.8-210)
P Value .493#
PTA, Percutaneous transluminal angioplasty.
Results are expressed as medians (IQ range).
*Friedman’s test for within group comparisons.
#Mann-Whitney test for between group comparisons.
Table IV. PDGF (pg/mL) before and after angioplasty
Treatment arm Baseline
Aspirin/Clopidogrel N  24 57.44 (16.56-131.13)
Aspirin/Placebo N  26 100.86 (16.46-198.22)
P Value# .540#
PTA, Percutaneous transluminal angioplasty.
Results are expressed as medians (IQ range).
*Friedman’s test for within group comparisons.
#Mann-Whitney test for between group comparisons.below the lowest limit of the ELISA kit, which was 15pg/ml. PDGF levels at baseline appeared higher in the
aspirin/placebo group compared with the aspirin/clopi-
dogrel group but this was not statistically significant
(Table IV).
In the aspirin/placebo group, there was no significant
difference in PDGF levels, pre-PTA or one hour post-PTA
compared with baseline. Treatment with clopidogrel was
associated with a significant decrease in PDGF levels fol-
lowing drug loading at the pre-PTA timepoint (P .004).
The levels remained low at the post-angioplasty time point,
but were not significant compared with baseline (Table
IV). This may be due to the small number of samples in
which PDGF was detectable. Between group comparison
showed that clopidogrel resulted in a significant decrease in
PDGF levels following drug loading at the pre-PTA time-
point (P  .004, Mann-Whitney). A subgroup analysis of
the 28 patients who were sampled at all five timepoints
revealed no significant changes in PDGF levels and no
difference between the two groups.
Markers of endothelial activation
Plasma sE-selectin. In both groups there were no
significant changes in sE-selectin levels following drug
loading or PTA (See Table V). There was also no significant
difference in soluble sE-selectin levels between the aspirin/
clopidogrel and aspirin/placebo groups at baseline, pre-
PTA, or one hour post-PTA timepoints. A subgroup anal-
ysis of the 28 patients who were sampled at all five
timepoints revealed no significant changes in sE-selectin
levels and no difference between the two groups.
Plasma sICAM-1. In the aspirin/clopidogrel group,
sICAM-1 levels were not significantly altered by loading
with 300 mg of clopidogrel or following PTA. sICAM-1
levels were significantly reduced following angioplasty in
ian ERK 1/2 activation
ding dose, pre-PTA One hour post-PTA P value
.5 (124.8-300) 217.5 ( 157.5-304.3) .001*
7 (145.8-243) 231.5 (133-305) .001*
.732# .901#
loading dose, pre-PTA One hour post-PTA P value
.03 (15.00-49.97) 29.83 (15.53-89.77) .009*
.80 (16.50-198.20) 59.20 (15.00-190.57) .723*
.033# .403#med
st loa
191
18Post
26
63the aspirin/placebo group (P  .016 compared with base-
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statistical differences between the groups at all timepoints
(Table VI). A subgroup analysis of the 28 patients who
were sampled at all five timepoints revealed no significant
changes in sICAM-1 levels and no difference between the
two groups.
von-Willebrand Factor. In the aspirin/clopidogrel
group, vWF levels were significantly higher than baseline
following loading with 300 mg of clopidogrel (P  .026).
In both groups, levels were unaltered following angioplasty
compared with baseline (Table VII). However, in the aspi-
rin/placebo group, there was a statistically significant de-
crease in vWF levels between drug loading and post-PTA
(P  .029). A subgroup analysis of the 28 patients who
were sampled at all five timepoints revealed no significant
changes in vWF levels and no difference between the two
groups.
DISCUSSION
The main finding of this study is that peripheral angio-
plasty increases the capacity of plasma to induce in vitro
proliferation of cultured smooth muscle cells, as assessed by
upregulation (phosphorylation) of ERK 1/2 (MAPKinase).
Table V. Soluble E-selectin (ng/mL) before and after ang
Treatment arm Baseline
Aspirin/Clopidogrel N  24 41.97 (26.03-68.33)
Aspirin/Placebo N  26 33.24 (24.24-46.56)
P Value .247#
PTA, Percutaneous transluminal angioplasty.
Results are expressed as medians (IQ range).
*Friedman’s test for within group comparisons.
#Mann-Whitney test for between group comparisons.
Table VI. Soluble ICAM-1 (ng/mL) before and after ang
Treatment arm Baseline
Aspirin/Clopidogrel N  24 405.25 (342.99-447.57)
Aspirin/Placebo N  26 393.30 (342.58-519.89)
P Value .587#
PTA, Percutaneous transluminal angioplasty.
Results are expressed as medians (IQ range).
*Friedman’s test for within group comparisons.
#Mann-Whitney test for between group comparisons.
Table VII. von Willebrand Factor (IU/mL) before and a
Treatment arm Baseline
Aspirin/Clopidogrel N  24 1.10 (0.76-1.83)
Aspirin/Placebo N  26 1.32 (1.12-1.75)
P Value .259#
PTA, Percutaneous transluminal angioplasty.
Results are expressed as medians (IQ range).
*Friedman’s test for within group comparisons.
#Mann-Whitney test for between group comparisons.Combination antiplatelet therapy, with clopidogrel plusaspirin, was effective in inhibition of platelet activation as
shown by a decrease in ADP-stimulated fibrinogen binding
and reduced plasma PDGF levels compared with aspirin
alone. However, the combination of clopidogrel and aspi-
rin therapy had no effect on SMC proliferative capacity
either at baseline or following peripheral angioplasty.
The experimental method used in this study to assess
proliferative capacity involved using the patients’ own
plasma to stimulate growth-arrested rat vascular SMCs.
There are no other documented studies using an ex-vivo
technique with human plasma following peripheral angio-
plasty. It should, however, be noted that the activation level
measured only equates to the potential of the patients’
plasma to stimulate SMCs and is therefore a surrogate
marker of SMC proliferation. A rise in ERK 1/2-stimulting
capacity is associated with PTA but is not reduced by aspirin
and clopidogrel treatment, compared with aspirin and pla-
cebo.
Studies have shown a marked increase in SMC activity
as assessed by ERK in balloon-injured rat arteries within 30
minutes of injury.9 This activity was still detectable at 12
hours, although by 24 hours post-injury had returned to
pre-injury levels. Other groups showed increased ERK2
asty
t loading, pre-PTA One hour post-PTA P value
.46 (22.68-55.51) 40.00 (19.72-53.66) .015*
.24 (23.66-48.65) 33.46 (23.18-49.40) .029*
.270# .674#
asty
t loading, pre-PTA One hour post-PTA P value
35 (357.92-453.69) 373.89 (330.28-462.84) .209*
20 (350.11-495.72) 391.92 (315.56-444.87) .031*
.828# .816#
ngioplasty
loading, pre-PTA One hour post-PTA P value
.31 (0.83-2.10) 1.36 (0.88-1.95) .022*
.62 (1.23-1.87) 1.31 (1.03-1.59) .042*
.391# .831#iopl
Pos
44
33iopl
Pos
402.
388.fter a
Post
1
1levels post-balloon angioplasty in rat carotid arteries, which
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days.10 Gennaro et al also demonstrated increased ERK1
and 2 activation post angioplasty in rabbit iliac arteries.11
Two previous studies have measured [3H] thymidine
uptake changes after coronary PTA as a marker of DNA
synthesis and an index of vascular SMC proliferation. Jo-
hansson et al showed that in 50 patients undergoing coro-
nary angioplasty, SMC stimulation was increased one hour
post-procedure compared with before (P  .001).12 Shi-
rotani et al found significantly increased SMC stimulation
in 21 patients with restenosis compared with 36 patients
without restenosis (P .001).13 In our study, there was no
significant difference in SMC activity in patients who had a
successful compared with unsuccessful PTA.
PDGF is a strong chemo-attractant for vascular SMCs.
Uchida et al identified that in rabbits undergoing femoral
arterial angioplasty, post-procedure there was increased an
mRNA expression of PDGF(-B), which correlated with
neointimal cellular proliferation.14 In rat carotid arteries, a
synthetic PDGF-BB antagonist significantly reduced inti-
mal hyperplasia following experimental injury.32 Human
studies in patients undergoing percutaneous transluminal
coronary artery angioplasty have shown that an increase in
PDGF obtained by coronary sinus sampling is a marker for
restenosis at six months post-procedure.33 It is unclear
from the present study if the reduction in PDGF by clopi-
dogrel and aspirin therapy prior to PTA will result in a
positive effect on neointimal cellular proliferation at a later
stage.
In the present study, peripheral angioplasty had a vari-
able effect on markers of endothelial activation. There were
no statistically significant changes in sE-selectin post-PTA,
and there was no additional effect of clopidogrel. Similar to
our study, Inoue et al showed that sE-selectin levels re-
mained stable in 19 patients undergoing peripheral angio-
plasty, and 25 patients undergoing coronary artery angio-
plasty.34 There was a statistically significant decrease in
sICAM-1 levels following PTA, in patients randomized to
receive placebo (P  .016). This drop was not seen in the
aspirin/clopidogrel patients and it may be that the trial
drug is masking an effect. Other researchers have found
varying results when analysing sICAM-1 levels post-PTA.
Tsakiris found a significant fall in sICAM-1 one hour
post-PTA in 71 patients undergoing femoro-popliteal
PTA.35 However, Heider et al showed no rise in ICAM-1
levels in 32 patients at 24 hours post-lower limb angio-
plasty.17
In our study, PTA also resulted in a significant decrease
in vWF levels in the aspirin/placebo patients, However,
those patients randomized to aspirin/clopidogrel had a
significant increase in vWF following trial drug loading and
no explanation can be offered for this. Other studies have
shown varying responses in vWF following angioplasty and
have attempted to link this with clinical outcome. Roller et
al showed that a rise in vWF following peripheral PTA was
associated with a higher incidence of restenosis.15 Similarly
Tsakiris showed that, of 71 patients undergoing femoro-
popliteal PTA, those developing late restenosis (n  30)had a trend for higher vWF levels, although this was not
statistically significant.35 We are unable to comment on the
possible relationship between rises in vWF or other markers
and medium term patency rates.
Study limitations
We acknowledge that the sample size of our study was
small, which may have lead to a type II error. The lack of a
full dataset (at 24 hours or 30 days post-angioplasty) has
not affected the study’s main findings of a rise in ERK 1/2
at one hour post-angioplasty, and a clopidogrel-induced
fall in PDGF. It may, however, have lead to an under-
estimation of the duration of these changes. ERK activation
(as it relates to cellular proliferation) has been linked to
sustained activation, which is seen at two to four hours
following angioplasty. We only used one hour, 24 hours,
and 30 days post-PTA timepoints, and therefore cannot
comment on any changes in ERK activation between these
points. However, it is likely that ERK 1/2 activation re-
mained elevated beyond the one hour time point.
External randomization removed any selection bias but
there were differences in sex distribution and a significant
difference in diabetes incidence between the two groups,
which was corrected for in multivariate analysis.
Technical aspects, such as very low sampled PDGF
values, could not be corrected for or improved by using
alternative assays. Furthermore, our results show significant
variation in the baseline levels, indicating that greater pa-
tient numbers would be required. Platelets, macrophages,
and endothelial cells can produce both PDGF chains (A
and B), whereas vascular SMC produce only PDGF-A
chains.36 As we only measured PDGF-BB, this did not
represent vascular SMC-produced PDGF and may have
only reflected platelet, macrophage, or endothelial-released
PDGF. However, PDGF-BB is known to be a potent SMC
stimulator.3
Another possible confounding factor is that in this
study, all sampling was from a peripheral vein rather than
the site of angioplasty. Markers of endothelial and smooth
muscle activation are likely to be higher at the site of injury
prior to dilution in the circulation. However, given the
repeated number of samples required and the time frame, it
was not considered ethical to take any form of sampling
other than peripheral venous blood. We took extra care in
our sampling procedures to avoid ex vivo activation of
platelets and coagulation during venepuncture and sample
handling; and plasma was centrifuged twice to remove
contaminating platelets before storage. Therefore, ex vivo
platelet release of factors such as PDGF and vWF would
have been minimized in our samples. The A7r5 rat cell line,
used for cell culture, exhibits very similar properties to
human vascular SMCs, is easy to maintain, and is very
homogenous. There are no available human smooth mus-
cle cell lines at present, such that experimentation using
human cells would require a primary culture resulting in
increased heterogeneity.
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This is the first study to show that in-vitro ERK 1/2
activation, which is intimately involved in smooth muscle
cell proliferation, increases after peripheral PTA. In this
study, clopidogrel and aspirin therapy had no demonstrable
effect on vascular SMC proliferative capacity. However, it
did reduce PDGF, which is known to be a potent smooth
muscle cell mitogen. It is unclear if this may affect subse-
quent restenosis. Further work is required to evaluate po-
tential therapeutic treatments which may reduce peripheral
PTA-induced smooth muscle cell activation.
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